Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review

  title={Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review},
  author={Aditya K. Gupta and Rachel R Mays and Sarah G. Versteeg and Neil H. Shear and Vincent Piguet and Bianca Maria Piraccini},
  journal={Clinical Drug Investigation},
Androgenetic alopecia (AGA) is characterized by non-scarring follicle miniaturization. Despite the success of approved therapies, commonly reported side effects and the need for continual use has led to the investigation of alternative therapies. The aim of this paper is to critically review the success of off-label, topical monotherapies for treatment of AGA in men. A literature search was conducted to obtain randomized, controlled and blinded studies that investigated off-label, topical… 
A randomized, single‐blinded, vehicle‐controlled study of a topical active blend in the treatment of androgenetic alopecia
A new topical active blend is effective in the treatment of AGA, with high degree of patients' satisfaction, improvement of quality of life, and an excellent safety profile, Thus, it may represent a useful alternative therapeutic approach for AGA.
Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia
Overall developed liposome loaded hydrogel system showed potential for effective and simultaneous delivery of both the drugs.


Pilot study of a novel treatment for androgenetic alopecia using enriched cell culture medium: clinical trials.
CCM was found effective in treating androgenetic alopecia in men and induced cessation of hair loss, increased rate of hair growth and appearance of new hair.
Topical valproic acid increases the hair count in male patients with androgenetic alopecia: A randomized, comparative, clinical feasibility study using phototrichogram analysis
Topical VPA increased the total hair counts of the authors' patients; therefore, it is a potential treatment option for androgenetic alopecia (AGA) and should be considered for further studies.
Treatment of androgenetic alopecia with a 7.5% herbal preparation
A group of 24 healthy male subjects under the age of 55 years with stage III-IV androgenetic alopecia were enrolled in a randomized double-blind parallel-group vehicle-controlled study lasting 48 weeks.
Topical adenosine increases the proportion of thick hair in Caucasian men with androgenetic alopecia
Adenosine is effective in increasing the proportion of thick hair in Caucasian men with AGA as well as in Japanese men and women.
Transdermal viprostol in the treatment of male pattern baldness.
  • E. Olsen, E. DeLong
  • Medicine, Psychology
    Journal of the American Academy of Dermatology
  • 1990
A mouse model of androgenetic alopecia.
The hypothesis that androgen-mediated hair loss is AR dependent and suggest that AR and beta-catenin mediate this effect are supported and can now be used to test new therapeutic agents for the treatment of AGA, accelerating the drug discovery process.
Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof‐of‐concept studies
A topical formulation of fulvestrant was developed for the potential treatment of androgenetic alopecia based on preclinical studies in mice in which topical fulvestant caused telogen hair follicles to enter anagen, thereby causing hair growth.
New Insight Into the Pathophysiology of Hair Loss Trigger a Paradigm Shift in the Treatment Approach.
Research points to similar dysregulation of intrinsic signaling pathways within follicle physiology that span the hair loss disorder spectrum - with a common inflammatory component identified in most hair loss pathogenesis, including that of androgenetic alopecia (AGA).